Abstract
Liver disease, a major health concern worldwide, is a serious and progressive disorder. Herein, we not only established a mouse model of DEN+CCl4-induced primary liver disease but also collected clinical human samples to investigate longitudinal alterations in the gut mycobiome. As liver disease advanced, gut integrity was disrupted, and the mycobiota was disturbed in the mouse models. The metabolites associated with hepatocellular carcinoma (HCC) differed from those associated with the cirrhotic phase as follows: levels of stercobilin and aflatoxin B1 dialcohol were reduced, while levels of triterpenoids, bafilomycin A1, and DHEA were increased in the HCC group. The abundance of the phylum Chytridiomycota increased as the chronic liver disease progressed and was then replaced by the phylum Ascomycota in HCC. Based on the results from clinical human samples, the genus Candida (Ascomycota) (in humans) and the genus Kazachstania (Ascomycota) (in mice) occupied a dominant position in the HCC group, while other fungi were depleted. The increased abundance of C. albicans and depletion of S. cerevisiae may be hallmarks of the progression of liver cirrhosis to early HCC. Moreover, the administration of C. albicans and S. cerevisiae in the LC-HCC progression could accelerate or retard the progression of HCC. Therefore, gut fungi have the potential to serve as a noninvasive clinical biomarker and even a treatment method.
Article PDF
References
Acharya, C., and Bajaj, J.S. (2021). Chronic liver diseases and the microbiome— translating our knowledge of gut microbiota to management of chronic liver disease. Gastroenterol 160, 556–572.
Albhaisi, S., Shamsaddini, A., Fagan, A., McGeorge, S., Sikaroodi, M., Gavis, E., Patel, S., Davis, B.C., Acharya, C., Sterling, R.K., et al. (2021). Gut microbial signature of hepatocellular cancer in men with cirrhosis. Liver Transpl 27, 629–640.
Augimeri, G., Fiorillo, M., Morelli, C., Panza, S., Giordano, C., Barone, I., Catalano, S., Sisci, D., Andò, S., and Bonofiglio, D. (2023). The ω-3 docosahexaenoyl ethanolamide reduces CCL5 secretion in triple negative breast cancer cells affecting tumor progression and macrophage recruitment. Cancers 15, 819.
Bajaj, J.S., Liu, E.J., Kheradman, R., Fagan, A., Heuman, D.M., White, M., Gavis, E.A., Hylemon, P., Sikaroodi, M., and Gillevet, P.M. (2018). Fungal dysbiosis in cirrhosis. Gut 67, 1146–1154.
Bi, C., Xiao, G., Liu, C., Yan, J., Chen, J., Si, W., Zhang, J., and Liu, Z. (2021). Molecular immune mechanism of intestinal microbiota and their metabolites in the occurrence and development of liver cancer. Front Cell Dev Biol 9, 702414.
Chappell, G., Kutanzi, K., Uehara, T., Tryndyak, V., Hong, H.H., Hoenerhoff, M., Beland, F.A., Rusyn, I., and Pogribny, I.P. (2014). Genetic and epigenetic changes in fibrosis-associated hepatocarcinogenesis in mice. Intl J Cancer 134, 2778–2788.
Chen, H.N., Chen, Y., Zhou, Z.G., Wei, Y., and Huang, C. (2019). A novel role for ketoconazole in hepatocellular carcinoma treatment: linking PTGS2 to mitophagy machinery. Autophagy 15, 733–734.
Chen, W., Wen, L., Bao, Y., Tang, Z., Zhao, J., Zhang, X., Wei, T., Zhang, J., Ma, T., Zhang, Q., et al. (2022). Gut flora disequilibrium promotes the initiation of liver cancer by modulating tryptophan metabolism and up-regulating SREBP2. Proc Natl Acad Sci USA 119, e2203894119.
Dapito, D.H., Mencin, A., Gwak, G.Y., Pradere, J.P., Jang, M.K., Mederacke, I., Caviglia, J.M., Khiabanian, H., Adeyemi, A., Bataller, R., et al. (2012). Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 21, 504–516.
de Bus, I., van Krimpen, S., Hooiveld, G.J., Boekschoten, M.V., Poland, M., Witkamp, R.F., Albada, B., and Balvers, M.G.J. (2021). Immunomodulating effects of 13- and 16-hydroxylated docosahexaenoyl ethanolamide in LPS stimulated RAW264.7 macrophages. Biochim Biophys Acta Mol Cell Biol Lipids 1866, 158908.
Deng, T., Li, J., He, B., Chen, B., Liu, F., Chen, Z., Zheng, J., Shi, Z., Zhang, T., Deng, L., et al. (2022). Gut microbiome alteration as a diagnostic tool and associated with inflammatory response marker in primary liver cancer. Hepatol Int 16, 99–111.
Gao, Y., Wang, J., Zhao, M., Xia, T., Liu, Q., Chen, N., Liao, W., Zeng, Z., You, F., and Zeng, J. (2022). Atractylenolide III attenuates angiogenesis in gastric precancerous lesions through the downregulation of δ-like ligand 4. Front Pharmacol 13, 797805.
Garcia-Hernandez, V., Quiros, M., and Nusrat, A. (2017). Intestinal epithelial claudins: expression and regulation in homeostasis and inflammation. Ann New York Acad Sci 1397, 66–79.
Hartmann, P., and Schnabl, B. (2023). Fungal infections and the fungal microbiome in hepatobiliary disorders. J Hepatol 78, 836–851.
Iida, N., Mizukoshi, E., Yamashita, T., Yutani, M., Seishima, J., Wang, Z., Arai, K., Okada, H., Yamashita, T., Sakai, Y., et al. (2021). Chronic liver disease enables gut Enterococcus faecalis colonization to promote liver carcinogenesis. Nat Cancer 2, 1039–1054.
Jia, W., Li, Y., Cheung, K.C.P., and Zheng, X. (2023). Bile acid signaling in the regulation of whole body metabolic and immunological homeostasis. Sci China Life Sci doi: https://doi.org/10.1007/s11427-023-2353-0.
Jiang, T.T., Shao, T.Y., Ang, W.X.G., Kinder, J.M., Turner, L.H., Pham, G., Whitt, J., Alenghat, T., and Way, S.S. (2017). Commensal fungi recapitulate the protective benefits of intestinal bacteria. Cell Host Microbe 22, 809–816.e4.
Kah, J., Wüstenberg, A., Keller, A.D., Sirma, H., Montalbano, R., Ocker, M., Volz, T., Dandri, M., Tiegs, G., and Sass, G. (2012). Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression. Oncol Rep 28, 1077–1083.
Kala, K., Pajqk, W., Sulkowska-Ziaja, K., Krakowska, A., Lazur, J., Fidurski, M., Marzec, K., Zięba, P., Fijalkowska, A., Szewczyk, A., et al. (2022). Hypsizygus marmoreus as a source of indole compounds and other bioactive substances with health-promoting activities. Molecules 27, 8917.
Lang, S., Duan, Y., Liu, J., Torralba, M.G., Kuelbs, C., Ventura-Cots, M., Abraldes, J.G., Bosques-Padilla, F., Verna, E.C., Brown, R.S., et al. (2020). Intestinal fungal dysbiosis and systemic immune response to fungi in patients with alcoholic hepatitis. Hepatol 71, 522–538.
Li, M., Yang, Z., Song, Z., Bo, C., Wang, S., and Jia, Q. (2023a). ATM deficiency aggravates the progression of liver fibrosis induced by carbon tetrachloride in mice. Toxicol 484, 153397.
Li, W., Xiao, J., Zhou, X., Xu, M., Hu, C., Xu, X., Lu, Y., Liu, C., Xue, S., Nie, L., et al. (2015). STK4 regulates TLR pathways and protects against chronic inflammation-related hepatocellular carcinoma. J Clin Invest 125, 4239–4254.
Li, Y., Wang, J., Li, L., Song, W., Li, M., Hua, X., Wang, Y., Yuan, J., and Xue, Z. (2023b). Natural products of pentacyclic triterpenoids: from discovery to heterologous biosynthesis. Nat Prod Rep 40, 1303–1353.
Liang, S., Ma, H.Y., Zhong, Z., Dhar, D., Liu, X., Xu, J., Koyama, Y., Nishio, T., Karin, D., Karin, G., et al. (2019). NADPH oxidase 1 in liver macrophages promotes inflammation and tumor development in mice. Gastroenterol 156, 1156–1172.e6.
Ling, Z., Xiao, H., and Chen, W. (2022). Gut microbiome: the cornerstone of life and health. Adv Gut Microbiome Res 2022, 1–3.
Liu, B., Zhou, Z., Jin, Y., Lu, J., Feng, D., Peng, R., Sun, H., Mu, X., Li, C., and Chen, Y. (2022a). Hepatic stellate cell activation and senescence induced by intrahepatic microbiota disturbances drive progression of liver cirrhosis toward hepatocellular carcinoma. J Immunother Cancer 10, e003069.
Liu, J., Geng, W., Sun, H., Liu, C., Huang, F., Cao, J., Xia, L., Zhao, H., Zhai, J., Li, Q., et al. (2022b). Integrative metabolomic characterisation identifies altered portal vein serum metabolome contributing to human hepatocellular carcinoma. Gut 71, 1203–1213.
Liu, Z., Li, Y., Li, C., Lei, G., Zhou, L., Chen, X., Jia, X., and Lu, Y. (2022c). Intestinal Candida albicans promotes hepatocarcinogenesis by up-regulating NLRP6. Front Microbiol 13, 812771.
Llovet, J.M., Kelley, R.K., Villanueva, A., Singal, A.G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., and Finn, R.S. (2021). Hepatocellular carcinoma. Nat Rev Dis Primers 7, 6.
Llovet, J.M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., and Gores, G. (2016). Hepatocellular carcinoma. Nat Rev Dis Primers 2, 16018.
Ma, J., Wang, R., Chen, Y., Wang, Z., and Dong, Y. (2023). 5-HT attenuates chronic stress-induced cognitive impairment in mice through intestinal flora disruption. J Neuroinflamm 20, 23.
Manogaran, S., Kilavan Packiam, K., Senthil Kumar, P., Rangasamy, G., and Saravanan, A. (2023). Utilization of industrial waste-liquid cheese whey for the batch fermentation of lovastatin using Fusarium nectrioides (MH173849) an endophytic fungus: screening, production and characterization. Chemosphere 318, 137947.
Naglik, J.R., FidelJr, P.L., and Odds, F.C. (2008). Animal models of mucosal Candida infection. Fems Microbiol Lett 283, 129–139.
Park, C.G., Kim, J.J., and Kim, H.K. (2020). Lipase-mediated synthesis of ricinoleic acid vanillyl ester and evaluation of antioxidant and antibacterial activity. Enzyme Microb Tech 133, 109454.
Qi, X., Chen, S., He, H., Wen, W., and Wang, H. (2021). The role and potential application of extracellular vesicles in liver cancer. Sci China Life Sci 64, 1281–1294.
Ren, Z., Li, A., Jiang, J., Zhou, L., Yu, Z., Lu, H., Xie, H., Chen, X., Shao, L., Zhang, R., et al. (2019). Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut 68, 1014–1023.
Rey, S., Quintavalle, C., Burmeister, K., Calabrese, D., Schlageter, M., Quagliata, L., Cathomas, G., Diebold, J., Molinolo, A., Heim, M.H., et al. (2017). Liver damage and senescence increases in patients developing hepatocellular carcinoma. J Gastro Hepatol 32, 1480–1486.
Roderburg, C., and Luedde, T. (2014). The role of the gut microbiome in the development and progression of liver cirrhosis and hepatocellular carcinoma. Gut Microbes 5, 441–445.
Sanada, S., Suzuki, T., Nagata, A., Hashidume, T., Yoshikawa, Y., and Miyoshi, N. (2020). Intestinal microbial metabolite stercobilin involvement in the chronic inflammation of ob/ob mice. Sci Rep 10, 6479.
Szóstak, N., Figlerowicz, M., and Philips, A. (2023). The emerging role of the gut mycobiome in liver diseases. Gut Microbes 15, 2211922.
Thoen, L.F.R., Guimarães, E.L.M., Dollé, L., Mannaerts, I., Najimi, M., Sokal, E., and van Grunsven, L.A. (2011). A role for autophagy during hepatic stellate cell activation. J Hepatol 55, 1353–1360.
Tonon, M., Angeli, P., and Piano, S. (2021). Bacterial infections in cirrhosis. Infect Microbes Dis 3, 117–124.
Trebicka, J., Bork, P., Krag, A., and Arumugam, M. (2021). Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure. Nat Rev Gastroenterol Hepatol 18, 167–180.
Villanueva, A. (2019). Hepatocellular carcinoma. N Engl J Med 380, 1450–1462.
Wang, C., Zhou, X., Wang, M., and Chen, X. (2021). The impact of SARS-CoV-2 on the human immune system and microbiome. Infect Microbes Dis 3, 14–21.
Wang, N., Liu, H., Liu, G., Li, M., He, X., Yin, C., Tu, Q., Shen, X., Bai, W., Wang, Q., et al. (2020a). Yeast β-D-glucan exerts antitumour activity in liver cancer through impairing autophagy and lysosomal function, promoting reactive oxygen species production and apoptosis. Redox Biol 32, 101495.
Wang, W., Dong, X.X., Liu, Y., Ni, B., Sai, N., You, L., Sun, M., Yao, Y., Qu, C., Yin, X., et al. (2020b). Itraconazole exerts anti-liver cancer potential through the Wnt, PI3K/AKT/mTOR, and ROS pathways. Biomed Pharmacother 131, 110661.
Weinmaier, T., Conzemius, R., Bergman, Y., Lewis, S., Jacobs, E.B., Tamma, P.D., Materna, A., Weinberger, J., Beisken, S., and Simner, P.J. (2023). Validation and application of long-read whole-genome sequencing for antimicrobial resistance gene detection and antimicrobial susceptibility testing. Antimicrob Agents Chemother 67, e0107222.
Wu, H.Y., Mortensen, U.H., Chang, F.R., and Tsai, H.Y. (2023). Whole genome sequence characterization of Aspergillus terreus ATCC 20541 and genome comparison of the fungi A. terreus. Sci Rep 13, 194.
Xue, C., Jia, J., Gu, X., Zhou, L., Lu, J., Zheng, Q., Su, Y., Zheng, S., and Li, L. (2022). Intratumoral bacteria interact with metabolites and genetic alterations in hepatocellular carcinoma. Sig Transduct Target Ther 7, 335.
Yu, L.X., and Schwabe, R.F. (2017). The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol 14, 527–539.
Zeng, S., Hartmann, P., Park, M., Duan, Y., Lang, S., Llorente, C., Wang, Y., Cabré, N., Fouts, D.E., Bacher, P., et al. (2023a). Malassezia restricta promotes alcohol-induced liver injury. Hepatol Commun 7, e0029.
Zeng, S., Rosati, E., Saggau, C., Messner, B., Chu, H., Duan, Y., Hartmann, P., Wang, Y., Ma, S., Huang, W.J.M., et al. (2023b). Candida albicans-specific Th17 cell-mediated response contributes to alcohol-associated liver disease. Cell Host Microbe 31, 389–404.e7.
Zhang, E.B., Zhang, X., Wang, K., Zhang, F., Chen, T.W., Ma, N., Ni, Q.Z., Wang, Y.K., Zheng, Q.W., Cao, H.J., et al. (2021). Antifungal agent Terbinafine restrains tumor growth in preclinical models of hepatocellular carcinoma via AMPK-mTOR axis. Oncogene 40, 5302–5313.
Zhang, F., Aschenbrenner, D., Yoo, J.Y., and Zuo, T. (2022a). The gut mycobiome in health, disease, and clinical applications in association with the gut bacterial microbiome assembly. Lancet Microbe 3, e969–e983.
Zhang, H., Wei, Y., Jia, H., Chen, D., Tang, X., Wang, J., Chen, M., and Guo, Y. (2022b). Immune activation of characteristic gut mycobiota Kazachstania pintolopesii on IL-23/IL-17R signaling in ankylosing spondylitis. Front Cell Infect Microbiol 12, 1035366.
Zhang, L., Chen, C., Chai, D., Li, C., Qiu, Z., Kuang, T., Liu, L., Deng, W., and Wang, W. (2023). Characterization of the intestinal fungal microbiome in patients with hepatocellular carcinoma. J Transl Med 21, 126.
Acknowledgement
This work was supported by the National Natural Science Foundation of China (81790631), the National Key Research and Development Program of China (2022YFC3602000), the Shandong Provincial Laboratory Project (SYS202202) and Research Project of Jinan Micro-ecological Biomedicine Shandong Laboratory (JNL-2022009B, JNL-2022047D).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The author(s) declare that they have no conflict of interest. Our research was approved by the Animal Experimental Ethical Inspection of the First Affiliated Hospital, Zhejiang University School of Medicine (Reference Number: 2022-1071), and the Clinical Research Ethics Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University (IIT20220494B).
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Jiang, S., Xu, L., Chen, Y. et al. Longitudinal gut fungal alterations and potential fungal biomarkers for the progression of primary liver disease. Sci. China Life Sci. (2024). https://doi.org/10.1007/s11427-023-2458-1
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s11427-023-2458-1